Europe Radiotherapy Market by equipment ( Radiation therapy stimulators, Treatment planning systems, Linear Accelerators), by type (External therapy, Intensity modulated therapy, External beam therapy, Image-guided radiation therapy, Stereotactic body radiation therapy, Intraoperative radiation therapy, Electron therapy, Proton Therapy, Tomotherapy, Internal therapy, Brachytherapy, Radioisotope or radionuclide therapy, Radioembolization) , by application ( Skin and lip cancer, Head and neck cancer, Breast cancer, Prostate cancer, Cervical cancer, Lung cancer, Spine cancer), end user ( Hospitals, Oncology centers, R&D centers, Diagnostic centers), Regions.

 

Europe Radiotherapy Market was valued at $5,650.2 Million in 2021 and is anticipated to grow at $7,198.4 Million till 2028 recording a CAGR of 3.82% during the forecast period 2022-2028. Europe Radiotherapy Market is a painless treatment which is extensively used in cancer treatment. It works on a principle of damaging cancerous cells by destruction of DNA inside cells by radiation.  It slows down the cancerous cells growth and provides comfort by relieving the patients with cancer symptoms. Cancer is the abnormal growth and spread of cells which arises from a change in single cell. Change may be due to external agents and inherited genetic factors and can affect almost any body part. Cancer can be prevented by avoiding exposure to the common risk factors, by surgery, radiotherapy and chemotherapy. Europe has wide variances in accessing radiation therapy services, scantiness in infrastructure and skilled professionals. As per, International Atomic Energy Agency (IAEA) report 2012, about 1286 radiotherapy centres registered in DIRAC database in Europe. Where Germany has the largest number with 289 centres, France with 177, Italy with 172 centres and Spain has 117 centres respectively. Netherlands and UK along with Nordic countries (Scandinavia, Finland and Iceland) have the most centralized radiotherapy infrastructure with more treatment equipment and fewer facilities at each centre. In February 2017, Elekta and European Society for Radiotherapy and Oncology (ESTRO) Cancer Foundation (ESF) to contribute the mission of “every patient in Europe will have access to state of the art of radiation. In June 2011, Cayman chemical company has adopted Genedata screener of Genedata, the company of advanced software solutions for drug discovery and life science research as a data management platform for cayman’s new epigenetic screening laboratory.